This September we are taking our successful Women in Biotech series to Cambridge, where we look forward to engaging with attendees to inspire more people to tackle diversity challenges within their organisations.
For this edition of the series we are encouraging women in the sector to bring a male colleague with them to the event. Nb. everyone planning to attend will need to register for the event.
We will be joined by some excellent speakers for a panel discussion, chaired by Sally Shorthose, which will focus on diversity challenges and how to address them in the working environment.
We look forward to seeing you at the Babraham Research Campus for an evening of enlightening discussion and networking.
17.00 - 17.30 Registration and networking
17:30 - 17:40 Welcome
17.40 - 18.30 Speaker discussion and Q&A
18.30 - 19.30 Networking and drinks
Babraham Research Campus
Sally has wealth of experience working with businesses at the cutting edge of research and technology and whose intellectual property is of prime importance.
Sally is one of our leading intellectual property (IP) partners. She provides a full range of intellectual property commercial advice and support to her clients, including licensing, partnering and exploitation agreements, research, development and marketing collaborations. She also frequently advises clients on regulatory and ‘freedom to operate’ matters, and manages significant due diligence matters. As a transactional intellectual property lawyer, she provides advice in relation to the protection and exploitation of a full range of IP rights, both in stand alone transactions and as part of an acquisition, divestment or investment activity.
Sally speaks on a variety of IP and regulatory life sciences topics at conferences and contributes to many leading publications; she is also the editor of the The Guide to EU Pharmaceutical Regulatory Law (published by Kluwer Law International), which is written entirely by the team at Bird & Bird with contributions from many offices. Sally is also leading the Bird & Bird Brexit Steering Committee; she gives regular talks and has published several articles on the implications of Brexit for the life sciences and medical devices industries.
Mihriban has been with F-star since 2008 and currently holds the position of SVP Drug Discovery, leading all internal and collaborative mAb2 discovery programmes. Prior to F-star she spent 6 years at Domantis/GSK Biopharm where she was involved in the discovery of domain antibodies, as well as technology development. Mihriban made the transition from academic research to industry after completing her PhD with Professor Dek Woolfson at the University of Sussex where she focused on the structure/stability engineering and design of small globular proteins.
Karolina joined Parkwalk Advisors' investment team in 2021. She has over a decade of experience building life sciences and healthcare companies within the Cambridge Cluster. Karolina played a pivotal role in securing pre-seed, seed, and Series A investments from a stellar syndicate of investors. In 2018 she co-founded and successfully delivered the first life sciences startup accelerator in Cambridge with a portfolio value of over £90m. She started her career as a scientist at a leading biopharmaceutical company delivering a portfolio of products to clinics. Karolina completed a PhD in protein folding/metabolic science from the University of Cambridge and carried out a drug development postdoc work at MedImmune/AstraZeneca.
Parkwalk Advisors is one of the UK’s leading growth fund managers, backing world-changing technologies emerging from UK universities and research institutions. Our unique asset class backs high-potential, hard science technology companies from a range of sectors, including life sciences, AI, big data, materials, medtech and much more.
BIA members - £25 + VAT
Non-members - £35 + VAT
BIA emerging companies or early stage non-member companies (in a company with less than 10 employees) or a university researcher - £20 + VAT *